AAJ HAS UPDATED ITS PRIVACY POLICY AND USES COOKIES ON THIS SITE. To acknowledge and accept AAJ’s privacy policy with the use of cookies, please select OK, I Accept.

Review AAJ's Privacy Policy
Navy watercolor gradient that gets light from left to right.
Close Alert
Registration is open!

2022 Annual Convention

July 16-19 | Seattle, WA

Build powerful connections and stay ahead of the curve.

Register Today

Litigation Packet

Litigation Packet

Pharmaceutical Products Liability Cases and the FDA

UpdatedDec 09, 2011
CreatedApr 05, 2006
Delivery method: Download
  • Provides plaintiff attorneys with the tools to pursue pharmaceutical products liability cases and addresses important issues relating to the FDA and drug companies
  • FDA prescription drug approval and post-market surveillance procedures, and their inherent flaws
  • Information on the symbiotic relationship between the FDA and the drug industry
  • Pharmaceutical marketing tactics, including the use of drug reps and ghostwritten medical literature, and the effect on the learned intermediary doctrine
  • Promotion of off-label use by drug companies, and the adverse effects  
  • Pharmacology and epidemiology, and their role in proving causation
  • Preemption issues and cases, including Mutual Pharmaceutical Company Inc. v. Bartlett, Wyeth v. LevinePliva, Inc. v. Mensing, and Riegel v. Medtronic
  • Sample complaints, client intake and evaluation forms, written discovery, and briefs
  • Obtaining electronically-maintained information in discovery and an explanation of the adverse event reporting system
  • Selecting and “Daubert-proofing” experts
  • Important statutory and regulatory materials